D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 87 Citations 22,822 360 World Ranking 7096 National Ranking 205

Overview

What is he best known for?

The fields of study he is best known for:

  • Cancer
  • Gene
  • Internal medicine

Giancarlo Pruneri focuses on Breast cancer, Internal medicine, Oncology, Cancer and Pathology. His research integrates issues of Clinical trial, Randomized controlled trial, Disease, Hazard ratio and Surgical oncology in his study of Breast cancer. The concepts of his Internal medicine study are interwoven with issues in Gastroenterology and Surgery.

His work carried out in the field of Oncology brings together such families of science as Survival rate, Estrogen receptor, Progesterone receptor, Tumor-infiltrating lymphocytes and Triple-negative breast cancer. In the subject of general Cancer, his work in Breast disease is often linked to MEDLINE, thereby combining diverse domains of study. His Pathology research is multidisciplinary, incorporating elements of Angiogenesis and Neovascularization.

His most cited work include:

  • The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014 (1126 citations)
  • Resting and activated endothelial cells are increased in the peripheral blood of cancer patients (392 citations)
  • Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type (323 citations)

What are the main themes of his work throughout his whole career to date?

Giancarlo Pruneri mostly deals with Internal medicine, Breast cancer, Oncology, Pathology and Cancer research. The study incorporates disciplines such as Gastroenterology and Surgery in addition to Internal medicine. His Breast cancer research is included under the broader classification of Cancer.

He studied Oncology and Carcinoma that intersect with Ductal carcinoma. His research in Pathology intersects with topics in Cyclin D1 and Angiogenesis. His Cancer research research incorporates themes from Carcinogenesis, Gene, Cancer cell and Gene mutation.

He most often published in these fields:

  • Internal medicine (64.52%)
  • Breast cancer (56.53%)
  • Oncology (51.27%)

What were the highlights of his more recent work (between 2018-2021)?

  • Internal medicine (64.52%)
  • Oncology (51.27%)
  • Breast cancer (56.53%)

In recent papers he was focusing on the following fields of study:

His primary areas of investigation include Internal medicine, Oncology, Breast cancer, Cancer research and Cancer. His work deals with themes such as Stage, Hormone receptor and Chemotherapy, Adjuvant therapy, which intersect with Oncology. His Chemotherapy study combines topics from a wide range of disciplines, such as Biopsy, Triple-negative breast cancer and Adenocarcinoma.

Giancarlo Pruneri works in the field of Breast cancer, focusing on Estrogen receptor in particular. The various areas that Giancarlo Pruneri examines in his Cancer research study include Cell, Carcinogenesis, Downregulation and upregulation, Metastasis and Epigenetics. Particularly relevant to Colorectal cancer is his body of work in Cancer.

Between 2018 and 2021, his most popular works were:

  • Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers (170 citations)
  • Antibody–Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non–small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade (157 citations)
  • ESO–ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4) (39 citations)

In his most recent research, the most cited papers focused on:

  • Cancer
  • Gene
  • Internal medicine

His primary scientific interests are in Internal medicine, Breast cancer, Oncology, Cancer research and Disease. His work in the fields of Breast cancer, such as Estrogen receptor, intersects with other areas such as MEDLINE. The Oncology study combines topics in areas such as Chemotherapy, Mutation, Tumor-infiltrating lymphocytes, Rituximab and Primary tumor.

His Cancer research study integrates concerns from other disciplines, such as Thyroid cancer, Carcinogenesis, Metastasis, Epigenetics and PTEN. His Disease research incorporates elements of Cancer and Healthcare system. His work in the fields of Paclitaxel overlaps with other areas such as Severe acute respiratory syndrome coronavirus 2.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014

R. Salgado;R. Salgado;C. Denkert;S. Demaria;N. Sirtaine.
Annals of Oncology (2015)

1424 Citations

Resting and activated endothelial cells are increased in the peripheral blood of cancer patients

Patrizia Mancuso;Alessandra Burlini;Giancarlo Pruneri;Aron Goldhirsch.
Blood (2001)

523 Citations

Multidisciplinary Meeting on Male Breast Cancer: Summary and Research Recommendations

Larissa A. Korde;Jo Anne Zujewski;Leah Kamin;Sharon Hermes Giordano.
Journal of Clinical Oncology (2010)

429 Citations

Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type

Annarita Conconi;Giovanni Martinelli;Catherine Thiéblemont;Andrés J M Ferreri.
Blood (2003)

427 Citations

Chemotherapy Is More Effective in Patients with Breast Cancer Not Expressing Steroid Hormone Receptors: A Study of Preoperative Treatment

Marco Colleoni;Giuseppe Viale;David Zahrieh;Giancarlo Pruneri.
Clinical Cancer Research (2004)

425 Citations

Angiogenesis in myelodysplastic syndromes

G Pruneri;F Bertolini;D Soligo;N Carboni.
British Journal of Cancer (1999)

360 Citations

The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study.

Stella Mook;Marjanka K. Schmidt;Giuseppe Viale;Giuseppe Viale;Giancarlo Pruneri;Giancarlo Pruneri.
Breast Cancer Research and Treatment (2009)

333 Citations

Predicting the Risk for Additional Axillary Metastases in Patients With Breast Carcinoma and Positive Sentinel Lymph Node Biopsy

Giuseppe Viale;Eugenio Maiorano;Giancarlo Pruneri;Mauro G. Mastropasqua.
Annals of Surgery (2005)

331 Citations

Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group Part 2 TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors

Shona Hendry;Roberto Salgado;Thomas Gevaert;Prudence A. Russell;Prudence A. Russell.
Advances in Anatomic Pathology (2017)

330 Citations

Clinical Activity of Rituximab in Gastric Marginal Zone Non-Hodgkin's Lymphoma Resistant to or Not Eligible for Anti–Helicobacter Pylori Therapy

Giovanni Martinelli;Daniele Laszlo;Andrés J M Ferreri;Giancarlo Pruneri.
Journal of Clinical Oncology (2005)

292 Citations

Editorial Boards

Tumori
(Impact Factor: 2.149)

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Giancarlo Pruneri

Giuseppe Viale

Giuseppe Viale

European Institute of Oncology

Publications: 133

Paolo Veronesi

Paolo Veronesi

European Institute of Oncology

Publications: 85

Sherene Loi

Sherene Loi

Peter MacCallum Cancer Centre

Publications: 67

Marco Colleoni

Marco Colleoni

European Institute of Oncology

Publications: 66

Emanuele Zucca

Emanuele Zucca

Universita della Svizzera Italiana

Publications: 59

Giuseppe Curigliano

Giuseppe Curigliano

European Institute of Oncology

Publications: 57

Francesco Bertoni

Francesco Bertoni

Institute of Oncology Research

Publications: 51

Antonino Neri

Antonino Neri

University of Milan

Publications: 48

Christos Sotiriou

Christos Sotiriou

Université Libre de Bruxelles

Publications: 46

Carsten Denkert

Carsten Denkert

Philipp University of Marburg

Publications: 43

Markus Raderer

Markus Raderer

Medical University of Vienna

Publications: 38

Fabrice Andre

Fabrice Andre

Institut Gustave Roussy

Publications: 37

Aron Goldhirsch

Aron Goldhirsch

European Institute of Oncology

Publications: 37

Pier Giuseppe Pelicci

Pier Giuseppe Pelicci

European Institute of Oncology

Publications: 36

Fatima Cardoso

Fatima Cardoso

Champalimaud Foundation

Publications: 35

Jorge S. Reis-Filho

Jorge S. Reis-Filho

Memorial Sloan Kettering Cancer Center

Publications: 33

Trending Scientists

Peter Buxmann

Peter Buxmann

TU Darmstadt

Aijun An

Aijun An

York University

Hai-Long Jiang

Hai-Long Jiang

University of Science and Technology of China

Dong Nyung Lee

Dong Nyung Lee

Seoul National University

Menachem Fromer

Menachem Fromer

Icahn School of Medicine at Mount Sinai

Örjan Carlborg

Örjan Carlborg

Uppsala University

Henry Daniell

Henry Daniell

University of Pennsylvania

James C. Cross

James C. Cross

University of Calgary

Qingchen Wang

Qingchen Wang

Chinese Academy of Sciences

Alistair Adcroft

Alistair Adcroft

Princeton University

Robert D. Nebes

Robert D. Nebes

University of Pittsburgh

Patrick Ragert

Patrick Ragert

Leipzig University

Josée Golay

Josée Golay

Mario Negri Institute for Pharmacological Research

John G. Holmes

John G. Holmes

University of Waterloo

Euan A. Ashley

Euan A. Ashley

Stanford University

Something went wrong. Please try again later.